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In lentiviral vector (LV) applications where transient transgene expression is sufficient, integrase-defective
lentiviral vectors (IDLVs) are beneficial for reducing the potential for off-target effects associated with inser-
tional mutagenesis. It was previously demonstrated that humanRPE65mRNA expression from an integrating
lentiviral vector (ILV) induces endogenous Rpe65 and Cralbp mRNA expression in murine bone marrow–
derived cells (BMDCs), initiating programming of the cells to retinal pigment epithelium (RPE)-like cells. These
cells regenerate RPE in retinal degeneration models when injected systemically. As transient expression of
RPE65 is sufficient to activate endogenous RPE-associated genes for programming BMDCs, use of an ILV is an
unnecessary risk. In this study, an IDLV expressing RPE65 (IDLV3-RPE65) was generated. Transduction
with IDLV3-RPE65 is less efficient than the integrating vector (ILV3-RPE65). Therefore, IDLV3-RPE65
transduction was enhanced with a combination of preloading 20 · -concentrated viral supernatant on
RetroNectin at a multiplicity of infection of 50 and transduction of BMDCs by low-speed centrifugation.
RPE65mRNA levels increased from*12-fold to*25-fold (p <0.05) aftermodification of the IDLV3-RPE65
transduction protocol, achieving expression similar to the*27-fold (p<0.05) increase observed with ILV3-
RPE65. Additionally, the study shows that the same preparation of RetroNectin can be used to coat up to
three wells with no reduction in transduction. Critically, IDLV3-RPE65 transduction initiates endogenous
Rpe65 mRNA expression in murine BMDCs and Cralbp/CRALBP mRNA in both murine and human
BMDCs, similar to expression observed in ILV3-RPE65-transduced cells. Systemic administration of ILV3-
RPE65 or IDLV3-RPE65 programmed BMDCs in a mouse model of retinal degeneration is sufficient to
retain visual function and reduce retinal degeneration compared to mice receiving no treatment or naı¨ve
BMDC. It is concluded that IDLV3-RPE65 is appropriate for programming BMDCs to RPE-like cells.
Keywords: bone marrow–derived cells, lentiviral vectors, transduction efficiency, integrase-defective
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INTRODUCTION
WE HAVE PREVIOUSLY DEMONSTRATED that systemic
delivery of immature bone marrow–derived cells
(BMDC; Lin–/Sca1+), programmed ex vivo by in-
serting a stable RPE65 transgene using an inte-
grating lentiviral vector (LV), can regenerate an
efficient and functional retinal pigment epithelial
(RPE) cell layer that restores visual function in
mouse models of retinal degeneration.1,2 This has
significant implications for the treatment of dry
age-related macular degeneration (AMD), which is
a major cause of vision loss in the elderly.3 The
primary defect in dry AMD is believed to be at the
RPE, which shows cellular dysfunction, atrophy,
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and cell loss, particularly in the central retina.4,5
The most viable and attractive option for target-
ing dry AMD is in the early stages by replace-
ment of damaged RPE using a minimally invasive
approach, such as systemic delivery of programmed
BMDC, as has been shown in animal models.1,2 As
success has been observed in murine models with
murine cells, it is necessary to optimize and further
develop the BMDC programming technique for safe
and efficient application in human cells.
It has previously been found that the expression
of the RPE65 transgene activates expression of
adenylate cyclase in BMDCs within hours of
transduction,2 and this in turn switches on ex-
pression of endogenous Rpe65 and RPE-associated
marker Cellular Retinaldehyde-Binding Protein-1
(Cralbp).2 It was therefore hypothesized that
transient expression of RPE65 from an integrase-
defective lentiviral vector (IDLV) may result in
sufficient programming in the absence of integra-
tion. Limiting integration significantly reduces the
risk of insertional mutagenesis, which can result
in deleterious effects resulting from LV insertion
in coding regions or regulatory elements.6–10 This
vector would be ideal for programming BMDCs for
use in human clinical trials.
IDLVs are known to be less efficient than inte-
grating lentiviral vectors (ILVs) for a number of
reasons, including low transduction rates and epi-
somal silencing.6,7,11 Silencing post transduction is
a significant concern for long-term expression of
a transgene from IDLVs in nondividing cells.11 For
this application, however, short-term expression of
RPE65 is thought to be sufficient for the pro-
gramming of BMDCs, as it has been shown that
cells express the endogenous Rpe65 and Cralbp
mRNAs within hours of transduction with the in-
tegrating RPE65 vector.1,2 This study therefore
focused on improving the protocol for transducing
BMDCs with IDLV-RPE65 to maximize the num-
ber of cells transduced with the vector.
The study demonstrated that IDLV3-RPE65
transduction can be increased by: (1) increasing the
concentration of the viral supernatant to reduce the
volume required to obtain a high multiplicity of in-
fection (MOI), (2) preloading viral supernatant on
RetroNectin prior to transduction, and (3) using a
spinoculation method to transduce the cells. In the
process of optimizing the protocol IDLV3-RPE65
transduction, measures were included to reduce the
costs associated with RetroNectin use for LV trans-
duction by: (1) confirming that using 2lg/cm2 to coat
plates is sufficient to achieve transduction with LVs,
as has been reported in retroviral vectors12; and (2)
reusing the 2lg/cm2 preparation to coat up to three
wells. IDLV3-RPE65-transduced in this manner in-
duces activation of the endogenous RPE-associated
genes Rpe65 and Cralbp in murine BMDCs and
CRALBP in human BMDCs at a similar level to
ILV3-RPE65 transduction. This indicates that
IDLV3-RPE65 is capable of initiating the differen-
tiation of both mouse and human BMDCs to RPE-
like cells in vitro, rendering them suitable for ther-
apeutic transplantation in dry AMD.
MATERIALS AND METHODS
Plasmids
A third-generation lentiviral vector expression
plasmid, pCDH-EF1-T2A-copGFP, was obtained
from Systems Biosciences (CD823A-1). RPE65
gene cDNA was obtained from GeneArt Gene
Synthesis Service and cloned into CD832A-1 by
Xba1/Sal1 (NewEnglandBiolabs; catalog #R0145S
and #R0138S) digestion of both plasmids and sub-
sequent ligation, placing RPE65 in frame with the
EF1 promoter and removing the T2A-cop-GFP re-
gion of the plasmid (pCDH-RPE65). T4 DNA li-
gase (New England Biolabs; catalog #M0202S) was
used to ligate the RPE65-containing fragment
with CD832A-1 with a 3:1 ratio of insert to vector.
Ligations were transformed into TOP10 bacteria,
screened, and verified by polymerase chain reac-
tion (PCR). Plasmid minipreps were used to obtain
plasmid for sequence verification and in the inter-
mediate stages of vector cloning, obtained using the
Qiagen Spin Miniprep Kit (catalog #27106). Packa-
ging plasmids pMDL and pMDL-D116N, and the
helper plasmid Rev, were obtained from Dr. Ken-
neth Cornetta (IU Vector Production Facility). The
envelope plasmid pcz-VSVGwas obtained fromDirk
Lindemann (DresdenUniversity). Plasmids used for
the production of lentiviruses were prepared by
maxiprep using thePureLinkHiPure Plasmid Filter
Maxiprep Kit from Invitrogen (catalog #K210017) or
Qiagen Plasmid Maxi Kit (catalog #12165). Plasmid
DNA concentration and quality wasmeasured using
the NanoDrop 2000 Spectrophotometer (Thermo
Fisher Scientific; catalog #SO6497).
Bacterial growth and transformation
All bacteria were grown in Luria-Bertani (LB)
broth (pH 7.5) or on LB agar supplemented
with 100 lg/mL of ampicillin (Thermo Fisher
Scientific; BP1760-25) or 50 lg/mL of kanamycin
(Teknova; K2127) as required. Prior to cloning, all
plasmids were transformed into dam/dcm-negative
Escherichia coli strain JM110 obtained from
Agilent (catalog #200239) due to the presence
of methylation-sensitive restriction sites in the
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cloning protocols. After cloning, plasmids were
transformed intoE. coliTOP10bacteria. pUC18and
sterile dH2O were used as positive and negative
controls, respectively.
Lentiviral production and titer
ILV3-RPE65 and IDLV3-RPE65 were produced
by co-transfection of viral production plasmids in
10 cm tissue culture plates containing 8· 106 HEK-
293T cells (HEK 293T/17 ATCC-CRL-11268) per
plate. DNAmixture for each plate was prepared as
follows: 1mL of plain Dulbecco’s modified Eagle’s
medium (DMEM) with 5 lg of pcz-VSVG, 10lg of
pCDH-RPE65 or pCDH-EF1-T2A-copGFP expres-
sion vector, 5lg of packaging plasmid pMDL
(for ILV3) or pMDL-D116N (for IDLV3), and 1 lg
of Rev. DNA mixture was added to 955lL of
plain DMEM containing 45lL of 1mg/mL poly-
ethylenimine (PEI; Sigma–Aldrich; catalog #9002-
98-6) and incubated at room temperature in the
dark for 20min. The DNA/PEI mixture for each
sample was then added to each plate containing
HEK-293T cells and incubated for 16h at 37C.
The medium was replaced with 5mL of fresh
completeDMEM, and the plateswere incubated for
24h. Viral supernatant was harvested and filtered
through a 0.45 lm polyethersulfone membrane
(Thermo Fish Scientific; Nalgene Filter Unit; cat-
alog #166-0045) and concentrated either by ultra-
centrifugation at 10,000 g for 1–4h or with Lenti-X
Concentrator reagent for 30min to a final concen-
tration of 10· or 20· as per the instruction manual
(ClonTech; catalog #PT4421-2). Supernatant was
re-suspended in phosphate-buffered saline (PBS)
or complete DMEM and titered in HT1080 cells.
Calculation of viral titer in the absence
of a selection marker
A standard curve was generated by comparing
2–DDCT values with flow cytometric data for green
fluorescent protein positive (GFP+) cells in order to
allow a comparison between 2–DDCT values and vi-
ral titer. A 2–DDCT value of 30 where 10lL of viral
supernatant was added per well containing 50,000
cells was considered to represent a viral titer of 108
at a MOI of 50; where a 2–DDCT value of 30 was
obtained with 2.5lL viral supernatant, viral titer
was*109 at a MOI of 50.
Animals and isolation of murine BMDC
C57BL6/J GFP+mice were used for the isolation
of Lin–/Sca1+ BMDC, as previously described.1,2
Animal procedures were performed according to IA-
CUC protocols #10568 and #11155 approved by the
IUSM IACUC. All procedures were performed ac-
cording to the Declaration of Helsinki and the ARVO
regulations for animal use. In brief, immediately
after sacrifice, the tibiae and fibiae were isolated,
and the bone marrow was flushed out of each bone
with PBS +1mMof EDTA, filtered through a 100lm
mesh cell strainer, re-suspended in PBS + EDTA,
and centrifuged at 300 g (Eppendorf Centrifuge
5804). Supernatant was discarded, and ammo-
nium chloride red blood cell lysis buffer was added.
After 15min on ice, the mixture was centrifuged at
300 g, and the cells were re-suspended in PBS +
EDTA at a concentration of 1· 108 cells/mL.
Lin–/Sca1+ BMDC selection
Lineage depletion was carried out using the
EasySep Mouse Hematopoietic Progenitor Cell
Enrichment Kit (catalog #19856). Following isola-
tion, cells were re-suspended at a concentration of
1 ·108 cells/mL in PBS + EDTA. Sca1 PE Positive
Labeling Reagent (20lL; Stemcell Technologies;
catalog #18756)wasaddedpermilliliter of cells.After
washing, cells were centrifuged at 350 g for 5min,
washed, and finally re-suspended at a concentra-
tion of 10 million cells/mL for fluorescent activated
cell sorting (FACS). Where GFP+ cells were used,
cells were sorted for double-positive GFP+ (cells)/PE
(Sca1+), with a 7–12% recovery. Where wild-type
cells were used, cells were sorted for PE (Sca1+), with
a 7–12% recovery. Sorted cells were post sorted to
verify purity and were typically >95% pure.
Isolation of human CD34+ BMDCs
Human CD34+ BMDCs were obtained from two
sources: (1) CD34+ cells with a purity >99% isolated
from cord blood, obtained from the Indiana Uni-
versity AngioBiocore; and (2) healthy donors (IRB
#160883855). White blood cells were isolated on a
Ficoll gradient followed by FACS for CD34+ cells
stained with AlexaFluor488 anti-human CD34
(BioLegend; catalog #344518) or bead separation
(Stemcell Technologies; EasySep Human CD34
Positive Selection Kit; catalog #18056).
LV transduction of cell lines and primary cells
Transductions were carried out using a number
of different methods to identify the optimum pro-
cedure. Briefly, BMDCswere transduced overnight
for 16h or by 2h of spinoculation at 150 g at
21C, with no reagent, polybrene, protamine, or
RetroNectin at a concentration of 0–12lg/mL ad-
ded to media, or on RetroNectin at 0–12 lg/cm2.
RetroNectin was either preloaded with vector for
30min at 37C prior to transduction, or cells and
vector were added together at the same time as the
transduction. RetroNectin was used to coat up to
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four plates per preparation. Cells were transduced
at a concentration of 5,000–100,000 cells/mL at an
MOI of 50, unless a higher or lower MOI is indi-
cated. Where polybrene or protamine sulfate was
used for in vitro experiments, polybrene was used
at a concentration of 8lg/mL, and protamine sul-
fate was used at a concentration of 10lg/mL.
Where RetroNectin plates or tubes were preloaded
with either cells or viral particles, preloading was
carried out for 30min at 37C in the lowest volume
of medium required to cover the surface of the
plates. Cells were harvested and prepared for RNA
analysis 4h after transduction.
Quantitative reverse transcription PCR
The RNAEasy Mini Kit was used for all RNA
isolations. cDNA (25ng) per microliter was reverse
transcribed using the iScript kit (BioRad; catalog
#1708891). BioRad SSoFast Advanced Universal
Probes Supermix kits (BioRad; catalog #1725284)
were used for all quantitative reverse transcription
PCR (qRT-PCR) assays in 10lL reactions. Where
available, BioRad PrimePCR validated primers
were used for all qRT-PCR experiments. Each
sample was prepared in triplicate, and each mea-
surement was made in triplicate to allow for sta-
tistical analysis. Positive PCR controls for RPE65
experiments consisted of cDNA prepared from
ARPE19 cells; for GFP experiments, positive con-
trols consisted of cDNA prepared from the bone
marrow of GFP+ mice. Negative controls for qRT-
PCRs consisted of a no-template control. Negative
controls for experiments consisted of untransduced
or untreated cells. GAPDH or beta-actin was used
as internal controls for all qRT-PCR experiments.
Samples were run on a BioRad CFX96 Touch Real-
Time PCR Detection System (BioRad; catalog
#1855195). The comparative CT (2–DDCT) method
was used for analyses.
Efficacy of ILV3 and IDLV3 in a murine model
of retinal degeneration
All animal studies were conducted under ap-
proved protocols by the Institutional Animal Care
and Use Committee at Indian University and in
accordance with guidelines set forth by the Na-
tional Institutes of Health and the Statement for
the Use of Animals in Ophthalmic and Visual Re-
search of theAssociation for Research inVision and
Ophthalmology. Adult (7- to 10-week-old) female
C57BL6/J mice and homozygous GFP transgenic
(C57BL/6-Tg [UBC-GFP]) were purchased from
Jackson Laboratories. Generation of SOD2 knock-
down mice and injection of BMDCs was performed
as previously described.1 In brief, the right eyes
of mice were injected sub-retinally with 1lL of
2.5· 1012 particles/mL of recombinant adeno-
associated virus serotype 1 (AAV1) constructs ex-
pressing SOD2-specific hammerhead ribozyme, or
rAAV-inactive ribozyme. At 1 month following
SOD2 knockdown, mice received a systemic injec-
tion of 5·104 null, ILV3-RPE65, or IDLV3-RPE65
programmed BMDCs in 100 lL of sterile saline
into the tail vein. Animals were then evaluated 3
months later. To evaluate the optokinetic re-
sponse, a computer-based visual acuity response
test was used (OptoMotryª 1.7.7 Cerebral Me-
chanics, Inc.). In brief, mice were tested for visual
acuity by observing optokinetic responses of mice
to rotating sinusoidal gratings.1 The OptoMotryª
program changed spatial frequency based on the
observer’s responses and tracked the responses
according to direction of pattern rotation to assess
the two eyes independently. For optical coherence
tomography (OCT), three lateral images (nasal,
central, and temporal) were collected, starting
0.4mm above the meridian crossing through the
center of the optic nerve (ON), at the ON merid-
ian, and 0.4mm below the ON meridian using
a Bipotogen SD-OCT. Upon completion of the
in vivo analyses, animals were terminated, and
eyes were enucleated. For some eyes, flat mount
RPE/choroid preparations were assessed by con-
focal imaging using an Olympus BX50 confocal
microscope to identify GFP+ donor cells.1 For
general histological analysis, eyes were fixed with
4% paraformaldehyde (Wako) and embedded in
paraffin, and 10 lm sections were stained with
hematoxylin and eosin according to standard
protocols.
Statistical analysis
All experiments were performed at least in trip-
licate. Results are expressed as mean– standard
error of the mean (SEM). Analysis of variance
with Tukey’s post hoc tests were carried out to de-
termine significance of results. Statistical analy-
sis was performed using Prism v5.01 (GraphPad
Software, Inc.), with p< 0.05 considered statisti-
cally significant.
RESULTS
Transduction of BMDCs with third-generation
ILV and IDLV vectors
Transduction of murine BMDCs with ILV3-
RPE65 at a MOI of 50 resulted in a *30-fold
(p <0.05) increase in expression of human RPE65
compared with the null control (Fig. 1A). Expres-
sion of murine Rpe65 mRNA was increased ap-
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proximately sixfold, and Cralbp approximately
fivefold (Fig. 1A). As expression of these endoge-
nous murine mRNAs is a critical step in BMDC
programming,1,2 it was concluded that ILV3-
RPE65 is appropriate for use in programming
BMDCs and for packaging as an IDLV. The aver-
age expression of humanRPE65 from ILV3-RPE65
in murine BMDCs was *28-fold (p< 0.05) higher
than expression in the untransduced control, and
expression of human RPE65 from IDLV3-RPE65
was *3.6-fold (p<0.05) lower than expression
obtained with ILV3-RPE65 at the same MOI
(Fig. 1B). The study therefore focused on improving
IDLV3-RPE65 transduction.
To confirm that IDLV3 vectors have limited in-
tegration potential, HT1080 cells were transduced
with IDLV3-GFP, and the percentage of GFP+ cells
was monitored for 12 days. This experiment was
carried out in a cell line as opposed to in murine or
human BMDCs due to previous observations that
BMDCs transduced with ILV or IDLV do not sur-
vive for sufficient time ex vivo for residual inte-
gration to be monitored. Expression of GFP from
IDLV3-GFP-transduced cells was significantly de-
creased (p< 0.05) at day 6 in comparison to day 1,
with a 2.1-fold decrease in expression of GFP at day
6 comparedwith day 1 (Fig. 1C). Expression of GFP
was almost absent by day 12 (Fig. 1C), with a 14.9-
Figure 1. Integrase-defective lentiviral vectors (IDLVs) infect murine bone marrow–derived cells (BMDCs) and induce expression of endogenous mRNA, and
transduce HT1080 cells with minimal integration. Murine Lin–/Sca1+ cells were infected with ILV3-RPE65 (A) or IDLV3-RPE65 (B) on RetroNectin by
centrifugation for 2 h at 150 g prior to harvest for quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis. HT1080 cells were infected
with IDLV3-GFP (C) or ILV3-GFP (D) with polybrene for 16 h and cultured for 1–12 days with green fluorescent protein (GFP) expression measured each day.
Uninfected cells were used as a negative control. For the GFP assays, cells stably expressing GFP were used as a positive control. (A) Expression of RPE65
mRNA from ILV3-RPE65 was *30-fold higher than in untreated cells. Cells also expressed the endogenous Rpe65 and Cralbp mRNA approximately six- and
fourfold higher than uninfected cells, respectively ( p< 0.05). (*p< 0.05; n = 9). (B) Expression of RPE65 mRNA from ILV3-RPE65 was *28-fold higher than
expression in the negative control ( p< 0.05). Expression of RPE65 mRNA from IDLV3-RPE65 was approximately eightfold higher than in the negative control
( p< 0.05). Expression of RPE65 was significantly lower from IDLV3-RPE65 than ILV3-RPE65 ( p > 0.05). (*p < 0.05; n = 3). (C) The percentage of cells expressing
GFP was measured each day. Between day 1 and day 6, expression of GFP reduced from*13% to*6% ( p < 0.05). Expression further reduced between day 6
and day 12 from*6% to*1% ( p< 0.05). (*p< 0.05; n= 3). (D) The percentage of cells expressing GFP was measured each day. Between day 1 and day 4, GFP
expression increased from *64% to 82% ( p < 0.05) before stabilizing at *75% through day 12. (*p < 0.05 [standard error of the mean (SEM)]; n = 3). All
statistical significance was calculated using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test.
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fold decrease in expression compared to day 1 and
a 7.2-fold decrease compared to day 6 (p< 0.05).
Overall, between day 1 and day 12, the percentage
of cells expressing GFP decreased from *13%
to*1% ( p < 0.05). The residual expression of GFP
retained at the end of the experiment is likely a
result of a small number of viral integrations,
as some residual integration does occur with
IDLVs.13 In contrast, ILV3-GFP stably integrates
into the genome, with expression rising from*65%
to *82% ( p < 0.05) from day 1 to day 4 before
stabilizing at *75% from day 5 through day 12
(Fig. 1D). Together, Fig. 1C and D show that
transduction with IDLV3-RPE65 or ILV3-RPE65
results in low integration and stable integration,
respectively.
Optimization of the use of RetroNectin
in the transduction of BMDCs
The co-localization of cells and LV particles is
critical for efficient transduction, and the goal of
transduction-promoting reagents such as polyca-
tions and the recombinant human fibronectin
fragment RetroNectin is to enhance the nonspecific
adhesion of the virions to the target cell sur-
face.12,14 Previously published experiments were
carried out using polybrene.1,2 However, as poly-
brene is known to be toxic to some cell lines and
primary cells, first transduction efficiencies were
compared with polybrene, the less toxic polycation
protamine sulfate, and RetroNectin.
ILV3-RPE65 and IDLV3-RPE65 transduction
with protamine sulfate was significantly less effi-
cient than transduction in the presence of poly-
brene or RetroNectin (p<0.05; Fig. 2A and B).
Protamine sulfate yielded an *8- and *11-fold
increase in RPE65 from ILV3-RPE65 in both mu-
rine and human BMDCs, respectively, whereas
polybrene or RetroNectin yielded a*25- and*24-
fold increase in ILV3-RPE65-transduced cells
(p <0.05; Fig. 2A). In IDLV3-RPE65-transduced
cells, an approximately five- and fourfold increase
in RPE65 was observed with protamine sulfate
in murine and human BMDCs, respectively,
compared to a *14- and 13-fold increase in the
presence of RetroNectin, and *12- and *13-fold
increase in the presence of polybrene ( p < 0.05;
Fig. 2B). Interestingly, combining RetroNectin
and polybrene together resulted in a lower trans-
duction efficiency than when each reagent was
used individually, with an average fold increase of
*28 ( p < 0.05) in RPE65 from ILV3-RPE65 when
used individually compared to an average fold
increase of *21.5 ( p < 0.05) when used together
(Fig. 2C). A similar effect was observed for both
murine and human BMDCs with IDLV3-RPE65,
with a*16-fold ( p < 0.05) increase in RPE65 with
both polybrene and RetroNectin individually com-
pared to a*13-fold (p<0.05) increase in expression
when used in combination (Fig. 2D).
The transduction efficiency of ILV3-RPE65 and
IDLV3-RPE65 vectors on increasing concentra-
tions of RetroNectin was compared to determine
the lowest concentration required to yield high
levels of transduction. The instruction manual
suggests a concentration of 4–20 lg/cm2, but it has
been reported that cells can be transduced with
retroviral vectors on 2 lg/cm2 RetroNectin.12 A
>25-fold (p <0.05) increase in RPE65 from ILV3-
RPE65 in both murine and human BMDCs was
Figure 2. Optimization of the use of RetroNectin for infection of BMDCs. Murine (Lin–/Sca1+) or human (CD34+) BMDCs were infected at a multiplicity of
infection (MOI) of 50 with ILV3-RPE65 or IDLV3-RPE65 with polybrene (8lg/lL), protamine sulfate (10lg/lL), or RetroNectin (2, 4, or 12 lg/lL; or 2, 4, or 12 lg/
cm2), or a combination of polybrene and RetroNectin (2lg/cm2). Cells were infected for 12 h and harvested for qRT-PCR analysis at 16 h. (A) Human RPE65
mRNA levels increased*25-fold (murine BMDCs) and*23-fold (human BMDCs) with ILV3-RPE65 infection on RetroNectin. Similar levels were observed with
polybrene: 24-fold ( p< 0.05) in the murine model and 23-fold ( p< 0.05) in the human model. Protamine sulfate was less effective, with around an eightfold
( p< 0.05; murine) and a*10-fold ( p < 0.05; human) increase in human RPE65 mRNA. (B) With IDLV3-RPE65, human RPE65 mRNA increased*15-fold ( p < 0.05;
murine) and *14-fold ( p < 0.05; human) with RetroNectin, 13-fold ( p< 0.05; murine) and 14-fold ( p < 0.05; human) with polybrene, and around sixfold ( p < 0.05;
murine) and fivefold ( p < 0.05; human) with protamine sulfate. (C) Human RPE65 mRNA levels were increased*29-fold (murine) and*28-fold (human) BMDCs
infected with RetroNectin, 27-fold ( p < 0.05; murine) and 28-fold ( p< 0.05; human) with polybrene, and *21-fold ( p< 0.05; murine) and *20-fold ( p < 0.05;
human) with RetroNectin and polybrene in combination. (D) Human RPE65 mRNA levels were increased*16-fold over control in human BMDCs infected with
ILDV3-RPE65 using RetroNectin, 16-fold ( p< 0.05) with polybrene, and *13-fold ( p < 0.05) with RetroNectin and polybrene in combination. (E) Murine and
human BMDCs infected with ILV3-RPE65 in the presence of 2lg/cm2 RetroNectin expressed human RPE65 mRNA mRNA 27- and 28-fold over control ( p < 0.05),
respectively. Expression was not increased in either cell type with an increase in RetroNectin concentration to 4 or 12 lg/cm2. (F) Murine and human BMDCs
infected with IDLV3-RPE65 in the presence of 2lg/cm2 RetroNectin expressed human RPE65 mRNA 13-fold over control ( p < 0.05) in both cell types. Expression
was not increased in either cell type with an increase in RetroNectin concentration to 4 or 12 lg/cm2. (G) Murine and human BMDCs infected with ILV3-RPE65
in the presence of 2 lg/cm2 RetroNectin used to coat one plate expressed human RPE65 mRNA 23- and 24-fold over control ( p < 0.05), respectively. Levels did
not increase or decrease in cells infected with ILV3-RPE65 in the presence of 2lg/cm2 RetroNectin used to coat two or three plates. In contrast, where 2lg/
cm2 RetroNectin was used to coat a fourth plate, RPE65 mRNA levels were only seven- and eightfold over control ( p< 0.05) in murine and human cells,
respectively. (H) Murine and human BMDCs infected with ILV3-RPE65 on 2 lg/cm2 RetroNectin-coated plates expressed human RPE65 mRNA 24- and 25-fold
over control, respectively ( p< 0.05). Cells transduced with media containing 2, 4, or 12 lg/lL RetroNectin did not significantly express RPE65 mRNA. (*p < 0.05
[SEM]; n= 3). All statistical significance was calculated using one-way ANOVA followed by Tukey’s multiple comparisons test.
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observed when transduced on 2lg/cm2 Retro-
Nectin (Fig. 2E). Transduction was not signifi-
cantly enhanced by transducing the cells on 4 or
12lg/cm2 RetroNectin (Fig. 2E). Similarly, trans-
duction with the IDLV results in a *12-fold
(p <0.05) increase in expression in murine and
human BMDCs transduced on 2lg/cm2 Retro-
Nectin, which is not significantly enhanced when
the concentration of RetroNectin is increased, with
a similar fold increase observed when cells are
transduced on 4 or 12lg/cm2 RetroNectin (Fig. 2F).
It was therefore confirmed that the use of 2 lg/cm2
RetroNectin is appropriate for transducing murine
and human BMDCs with ILV3-RPE65 and IDLV3-
RPE65. Using a smaller volume of RetroNectinwas
not found to facilitate transduction as efficiently as
2 lg/cm2 (Fig. 2E).
Next, the binding capacity of RetroNectin when
used to coat multiple plates was investigated. In-
stead of discarding the RetroNectin after coating
the first plate, it was transferred to a new plate,
and the coating procedure was repeated up to three
times. As shown in Fig. 2G, RPE65 expression in
both human and murine BMDCs transduced with
ILV3-RPE65 was found to be *27-fold (p< 0.05)
higher than in the control in cells transduced
on RetroNectin used once, twice, and three times.
In contrast, on the fourth use of RetroNectin,
RPE65 levels dropped to around eightfold over the
control, indicating that RetroNectin cannot be
used more than three times (Fig. 2G). Consistent
with ILV3-RPE65 data, BMDCs transduced with
IDLV3-RPE65 on plates coated with RetroNectin
once, twice, three times, or four times expressed
RPE65*4-,*4-,*7-, and 0.85-fold over the control,
respectively. This further indicates that RetroNectin
can be used multiple times prior to a reduction in
transduction efficiency (Fig. 2G).
Finally, the study investigated whether adding
RetroNectin to the medium could also facilitate
transduction. RetroNectin was added to the me-
dium at a concentration of 0–12 lg/lL, and human
RPE65 levels were compared to those achieved on
plates coated with 2 lg/cm2 RetroNectin following
transduction with ILV3-RPE65 or IDLV3-RPE65.
Adding RetroNectin to the culture medium does
not facilitate ILV3-RPE65 or IDLV3-RPE65
transduction of murine or human BMDCs, with no
significant increase in RPE65 expression observed
(Fig. 2H). By contrast, cells transduced with 2, 4, or
12lg/mLRetroNectin in themediumwere found to
express RPE65 *16, *10, and *8-fold (p< 0.05)
less, respectively (Fig. 2H).
Enhancing the transduction of BMDCs
with IDLV3-RPE65
IDLV3-RPE65 transduces murine and human
cells at a lower efficiency than ILV3-RPE65 at the
same MOI (Figs. 1 and 2). RPE65 levels following
IDLV3-RPE65 transduction are approximately
8- to 15-fold higher than control in IDLV3-RPE65-
transduced cells, whereas in ILV3-RPE65-
transduced cells, RPE65 levels are 27- to 30-fold
higher than control. This is consistent with previ-
ously reported findings that IDLVs do not trans-
duce as efficiently as ILVs.7 As maximizing the
number of transduced cells is advantageous,
methods by which IDLV3-RPE65 transduction of
BMDCs could be enhanced were investigated.
Here, the focuswas primarily onmurineBMDCs as
Figure 3. Enhancing the infection of BMDCs with IDLV3-RPE65. Murine (Lin–/Sca1+) or human (CD34+) BMDCs were infected ILV3-RPE65 or IDLV-RPE65 (at a
MOI of 50 (A, C–G), 100 (A), or 500 (A), or with 20 lL concentrated viral supernatant (B). RetroNectin at 2lg/cm2 was used for all transductions, and was
either used by itself (A–C) or with preloading of vectors (D–G) or cells (F). Cells were infected for 12 h and harvested for analysis at 16 h unless spinoculated
(G), where cells were infected for 2 h at 150 g and harvested for analysis at 4 h. (A) Increasing the MOI of ILV3-RPE65 increased RPE65 mRNA levels
from *27-fold over control ( p < 0.05) at MOI 50 to *68-fold over control ( p < 0.05) at MOI 100 and *150-fold over control ( p < 0.05) with MOI 500. Increasing
the MOI of IDLV3-RPE65 did had no significant effect on expression, with RPE65 levels remaining at around sevenfold over control ( p< 0.05). (B) Centrifugation
of IDLV3-RPE65 supernatant for 2 h increased recovery of virions, with a*10-fold increase in infection of murine BMDCs with concentrated supernatant at the
same volume in comparison to eightfold observed at 1 h. Centrifugation for 3 h did not enhance infection efficiency, and centrifuging for 4 h reduced the viability
of virions, with RPE65 expression only threefold over control ( p < 0.05). (C) Concentrating viral supernatant 20 · enhanced the infection of IDLV3-RPE65 in
comparison with concentrating 10 · and infecting at the same MOI, with a 19-fold ( p< 0.05) increase in RPE65 mRNA observed at a MOI of 50 with the
10 · concentrated vector and 10-fold ( p < 0.05) with the 20 · concentrated vector at the same MOI. (D) Preloading ILV3-RPE65 on RetroNectin for 30 min prior to
adding murine BMDCs did not enhance infection, with a 28-fold increase ( p< 0.05) observed with or without preloading. In contrast, with IDLV3-RPE65,
preloading increased RPE65 expression from 15-fold over control ( p< 0.05) to 23-fold over control ( p< 0.05). (E) Preloading ILV3-RPE65 on RetroNectin up to
three times did not result in an increase in human RPE65 expression. Preloading IDLV3-RPE65 twice increased infection, with RPE65 mRNA levels increasing
from 21- to 24-fold over control ( p< 0.05). No increase was observed with three preloads. (F) Murine BMDCs transduced with IDLV-RPE65 expressed RPE65
at the highest level when viral particles were preloaded onto RetroNectin, with a 24-fold increase ( p< 0.05) in expression versus 10-fold with no preload
(p < 0.05). Preloading the cells instead of the vector yielded an increase in RPE65 expression, with a 17-fold increase versus control ( p < 0.05). However, this
was lower than observed when viral particles were preloaded, indicating no advantage in preloading cells (G) IDLV-RPE65 infects murine BMDCs at the
highest efficiency when the vector is preloaded onto RetroNectin followed by infection by spinoculation, with an 26-fold increase ( p < 0.05) in expression over
control in comparison to a 20-fold increase with preload alone ( p< 0.05), and a 22-fold increase with spinoculation alone ( p< 0.05). (*p < 0.05 [SEM]; n= 3). All
statistical significance was calculated using one-way ANOVA followed by Tukey’s multiple comparisons test.
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opposed to human BMDCs due to the necessity of
establishing the use of IDLV3-RPE65 therapeuti-
cally in murine BMDCs prior to testing in our
mouse model of retinal degeneration.
Increasing the MOI does not significantly en-
hance expression in murine BMDCs cells trans-
duced with IDLV3-RPE65, with RPE65 expression
remaining at around two- to threefold over control
in IDLV3-RPE65-transduced cells, despite an in-
crease of the MOI from 50 to 500 (Fig. 3A). In
contrast, increasing the MOI of ILV3-RPE65 from
50 to 500 significantly enhancesRPE65 expression,
with a*18-fold (p< 0.05) increase over the control
with MOI 50, and a*500-fold increase at MOI 500
(p <0.05). As increasing the MOI did not enhance
IDLV transduction, next the procedure by which
the viral particles were concentrated was modified.
Increasing the centrifugation time from 1 to 2h
increased the virion recovery of IDLV3-RPE65,
with an increase in human RPE65 in cells trans-
duced with 20 lL of supernatant from around
eightfold over control at 1 h to*12-fold over control
at 2h (Fig. 3B). Further increasing the concentra-
tion time to 3h did not enhance virion recovery.
Additionally, centrifuging the viral particles for 4h
significantly reduced recovery, with RPE65 ex-
pression observed at less than fivefold over the
control in BMDCs transduced with 20 lL of IDLV3-
RPE65 supernatant.
To investigate further whether the concentra-
tion protocol could be modified to enhance IDLV3-
RPE65 transduction, the viral supernatant was
concentrated with LentiX Lentiviral Vector Con-
centratingReagent (catalog #PT4421-2; ClonTech).
Concentrating the viral supernatant 10·with
LentiX resulted in a *12-fold (p< 0.05) increase
in expression over the control when transduced at
an MOI of 50. IDLV3-RPE65 concentrated at
20· resulted in a significant increase in RPE65,
with a*20-fold (p <0.05) increase at the sameMOI
(Fig. 3C).
While Lenti-X concentration of IDLV3-RPE65
enhanced transduction efficiency in comparison
with the centrifugation-concentrated vector, the
efficiency was still lower than that of ILV3-RPE65,
with a*20-fold increase with IDLV3-RPE65 com-
pared to an average 27-fold increase with ILV3-
RPE65. It has been reported that preloading
retroviral vectors onto RetroNectin, either once
or up to five times, significantly enhances gene
transfer.12 Therefore, the use of preloading in
ILV3-RPE65 and IDLV3-RPE65 transductionswas
evaluated. RPE65 levels after ILV3-RPE65 trans-
duction remained at *27-fold (p< 0.05) over con-
trol when murine BMDCs were transduced with
orwithout preloading (Fig. 3D). In contrast,RPE65
expression increased from*13-fold (p< 0.05) over
control on RetroNectin alone to*23-fold (p< 0.05)
in murine BMDCs transduced with IDLV3-RPE65
preloaded on the RetroNectin (Fig. 3D). Preloading
the plate twice enhances IDLV3-RPE65 trans-
duction (p< 0.05; Fig. 3E). No significant improve-
mentwas observed between two and three preloads
(Fig. 3E).
As RetroNectin binds to both the vector and the
cells, transduction on plates that had been pre-
loaded with cells prior to the addition of the vector
was also considered. No advantage in preloading
cells in comparison with preloading viral super-
natant was observed (Fig. 3F).
Despite the increase in IDLV3-RPE65 transduc-
tion with preloading, RPE65 levels were still lower
(*23-fold over control) than those obtained with
ILV3-RPE65 (*27-fold over control). As a final
modification to the protocol, RetroNectin preloading
was combined with transduction by centrifugation,
referred to as spinoculation. Spinoculating murine
BMDCs with preloaded IDLV3-RPE65 results in
a*27-fold increase in expression of the vectorwhen
combined with preloading on RetroNectin without
spinoculation (p<0.05; Fig. 3G).
The study therefore demonstrated that concen-
trating IDLV3-RPE65 20·with LentiX followed
by transduction of cells on 2lg/cm2 RetroNectin,
preloaded with the vector at a MOI of 50, with
spinoculation, increases RPE65 expression at a
similar level to ILV3-RPE65.
In vitro differentiation of human and murine
BMDCs with IDLV3-RPE65
It was previously reported that transduction of
murine BMDCs with an integrating lentiviral
vector expressingRPE65 initiates expression of the
endogenous murine Rpe65 and Cralbp mRNAs
(Fig. 1A).1,2 Murine BMDCs transduced with ei-
ther ILV3-RPE65 (Fig. 1A) or IDLV3-RPE65 vec-
tors (Fig. 4A) express endogenous Rpe65, and
Cralbp mRNAs 5- to 10-fold (p <0.05) over control
(Fig. 4A). This indicates that IDLV3-RPE65 is
likely to be sufficient for promoting the expression
of the RPE-associated genes that contribute to
the programming of the BMDCs to RPE-like cells.
In human BMDCs, an approximately fivefold in-
crease in expression of CRALBP mRNA is ob-
served in cells transduced with either ILV3-RPE65
or IDLV3-RPE65 (Fig. 4B). This indicates that
IDLV3-RPE65 may also be capable of promoting
differentiation of human BMDCs to RPE-like cells.
While the relative contribution of the exogenous
(i.e., vector-derived) RPE65 in comparison to the
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endogenous Rpe65 gene is not currently known, it
is proposed that activation of the endogenous
Rpe65 is likely to be critical for adequate cellular
reprogramming. It was observed that Rpe65 acti-
vation also results in a lack of Cralbp activation in
murine BMDCs, suggesting a role forRpe65 versus
RPE65 specifically in programming the BMDCs.
Efficacy of ILV3 and IDLV3 in a murine model
of retinal degeneration
Rescue of visual function can be assessed using
the optokinetic response, which is determined by
measuring the spatial frequency of head turning
in response to an image. The optokinetic response
was greatly reduced following SOD2 knock-
down compared to control mice (Fig. 5A), and this
was not improved by systemic administration of
naı¨ve BMDC. However, a significant improve-
ment (>60%; p< 0.05) in optokinetic response was
observed in animals 3 months after receiving
systemic BMDC-ILV3-RPE65 or BMDC-IDLV3-
RPE65 (Fig. 5A). OCT assessment demonstrated
normal retinal architecture in untreated eyes.
However, SOD2 knockdown resulted in significant
abnormalities in SOD2 eyes at 4 months following
knockdown, as reported previously,1 and this was
not reversed by the systemic administration of
naı¨ve BMDCs (Fig. 5B). By contrast, animals 3
months after receiving systemic BMDC-ILV3-
RPE65 or BMDC-IDLV3-RPE65 demonstrated
near normal retinal architecture (Fig. 5B). In
agreement with previous observations,1 RPE flat
mounts demonstrated the typical appearance of
GFP+ BMDCs in mice receiving systemic BMDC-
ILV3-RPE65 or BMDC-IDLV3-RPE65 (Fig. 5C).
Only minimal numbers of GFP+ BMDCs were
observed in animals receiving naı¨ve BMDCs. Pa-
thology in the SOD2 knockdown retinas demon-
strated vacuolation and atrophy of the RPE
together with degeneration of the photoreceptors
(Fig. 5D). Mice treated with control naı¨ve BMDCs
demonstrated similar progressive pathology to
that of untreated SOD2 knockdown mice. By con-
trast, mice receiving systemic BMDC-ILV3-RPE65
or BMDC-IDLV3-RPE65 demonstrated a mature,
highly pigmented epithelial layer, with RPE mor-
phology consistent with the normal controls, and
the morphology of the neural retina was greatly
improved (Fig. 5D).
DISCUSSION
It was previously shown in twomurinemodels of
RPE damage that adult BMDCs modified ex vivo
with an ILV expressing RPE65 migrate to and
preserve the RPE and retina following systemic
delivery.1,2 Compounding factors facilitating the
lack of visual recovery in humans after cell-based
therapy for dryAMD to date15–17 include treatment
in the late stages of disease, limitedmotility of cells
across the RPE layer post-injection, and side effects
of invasive cell delivery.1,2,18–20 The systemic-
delivery approach eliminates the need for invasive
sub-retinal surgery, allowing for early interven-
tion. The cells are more likely to integrate across
Figure 4. In vitro differentiation of human and murine BMDCs with IDLV3-RPE65. Murine Lin–/Sca1+ BMDCs (A) or human CD34+ cells (B) were transduced
with ILV3-RPE65 on RetroNectin by spinoculation for 2 h at 150 g, or with IDLV3-RPE65 preloaded on RetroNectin prior to spinoculation. Cells were then
harvested and lysed for qRT-PCR analysis. RPE65 expression was *32-fold over control and *28-fold over control in murine (A) and human (B) BMDCs
infected with ILV3-RPE65, respectively ( p< 0.05). RPE65 mRNA levels were *24-fold over control in both murine (A) and human (B) BMDCs, respectively
( p< 0.05). In murine BMDCs, endogenous Rpe65 mRNA levels were increased around six- and sevenfold versus control in cells transduced with ILV3-RPE65
and IDLV3-RPE65, respectively, and Cralbp mRNA levels were increased seven- and eightfold versus control in cells transduced with ILV3-RPE65 and IDLV3-
RPE65, respectively (A). In human BMDCs, CRALBP mRNA levels were fivefold over control in cells transduced with either vector. (*p< 0.05 [SEM]; n= 12
[murine BMDC, ILV3-RPE65]; n = 3 [human BMDC, ILV3-RPE65; murine and human BMDC, IDLV3-RPE65]). All statistical significance was calculated using one-
way ANOVA followed by Tukey’s multiple comparisons test.
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the RPE layer and at focal points of injury due to
their recruitment from the bloodstream.21,22
Transient expression of RPE65 is likely to be
sufficient, as it was previously reported that the
endogenous Rpe65 and Cralbp genes are activated
within hours of RPE65 vector transduction.1,2
IDLVs lack the integrase gene, and integrate at
a 500- to 1,250-fold lower rate than integrating
vectors,13 with residual integration likely occur-
ring through integrase-independentmechanisms,23
Figure 5. Efficacy of ILV3 and IDLV3 programmed BMDCs in a murine model of retinal degeneration. C57BL6/J mice received sub-retinal injection of AAV1-Rz-
SOD2 or AAV1-Rz-inactive 1 month prior to tail-vein injections of naı¨ve GFP+ murine BMDCs (null) or GFP+ BMDCs programmed with ILV3-RPE65 or IDLV3-RPE65.
Animals were assessed 3 months following administration of BDMCs. (A) Visual acuity testing using an Optomotor behavioral test demonstrated recovery of
optokinetic response in SOD2 knockdown mice receiving ILV3-RPE65-programmed BMDCs or IDLV3-RPE65-programmed BMDCs, which was not observed in
animal receiving naı¨ve BMDCs (null). A comparison of average values for photopic activities in response to rotating sinusoidal gratings is shown for each group of
mice (n = 5 per group) as mean– SEM. (B) Spectral domain optical coherence tomography (SD-OCT) was used to examine retinal morphology of the mouse retina
in vivo. Major abnormalities were observed in the RPE/photoreceptor layer in RzSOD2 knockdown eyes with or without null BMDC treatment. However, the RzSOD2
knockdown eyes that received the ILV3-RPE65-programmed BMDC or IDLV3-RPE65-programmed BMDC treatments show near-normal retina architectures. (C)
Representative fluorescent micrographs of flat-mounted RPE showing the presence of significant numbers of GFP+ (green) IDLV3-RPE65-BMDC and ILV3-RPE65-
BMDCs. Only very few GFP+ cells were observed in mice treated systemically with null BMDCs. (D) Representative photomicrographs of 6lM hematoxylin and
eosin–stained cross-sections of the retina/choroid/sclera showed significant disruption of the RPE layer in the SOD2-KD mice, which was largely absent in mice
receiving either ILV3-RPE65-programmed BMDC or IDLV3-RPE65-programmed BMDC, which both showed much improved retinal morphology. Higher magnifi-
cation images of the RPE layer demonstrated that systemic administration of RPE65-programmed BMDCs with either ILV3 or IDLV3 have a near normal RPE
morphology, similar to inactive Rz injected eyes. This was not apparent in animals receiving null BMDCs, in which there is thinning of the retina and severe loss of
the RPE cells. RGC, retinal ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium; CHO, choroid.
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such as DNA break-induced non-LTR-mediated
integration.24 In a clinical setting, inclusion of a
suicide gene in the transducing vector would allow
for rapid elimination of cells containing integrated
vector if off-target effects resulting from insertional
mutagenesis were to occur. Suicide gene-mediated
inducible apoptosis has been demonstrated to
be safe and effective in human clinical trials.25,26
The findings are consistent with observations
that low-level transgene expression is maintained
10–14 days post transduction.27–29 Residual inte-
gration is, however, not considered to be a signif-
icant concern, considering that even integrating
vectors that have been modified to self-inactivate,
as is now standard practice for the use of LV vec-
tors, do not promote oncogenesis, even in murine
models that are tumor prone.30
It has been well established in the literature
that IDLVs are less efficient than ILVs.6,7 Critical
difficulties in the application of IDLVs have arisen
for a number of reasons, primarily a low number
of virions entering cells,6 and downregulation of
transgene expression due to episome inhibition,11
which has been shown to be counteracted by a de-
letion in the U3 region of the vector.11 Several
groups have published modifications to the trans-
ducing vector which improve the stability of ex-
pression from episomal IDLV particles. These
modifications include codon-optimization of the
transgene,31,32 the use of a strong promoter such as
SV4033 instead of the CMV promoter, which is
susceptible to silencing,34 and inhibiting viral life-
cycle proteins.35,36 Some of these modifications
have been utilized in this study through the use of
the EF-1 promoter, which is constitutively ex-
pressed at a similar level in all cell types, and
codon-optimization of the RPE65 cDNA for use in
human cells.
Overall, the focus was on increasing the number
of virions entering cells as opposed tomodifying the
transducing vector further, as retention of trans-
gene expression was not thought to be required for
the application. The critical difference between the
use of IDLV3-RPE65 in this study and themajority
of IDLV3-based studies published to date is that
expression of RPE65 in this study was only re-
quired at a high level for a few hours post trans-
duction for the vector to activate the endogenous
genes, and therefore it was being used as a mo-
lecular ‘‘switch’’ as opposed to a long-term modi-
fication. Consequently, expression was measured
at 4 h post transduction, which is in contrast
with typical LV expression studies that measure
transgene expression after several days in cul-
ture.6,7,11,13,29,32,33,36–45 This time point was chosen,
as it has previously been demonstrated that RPE65
induces Rpe65 and Cralbp expression within the
first few hours of transduction.2
It is proposed that the method outlined here is
optimal for the application of IDLVs in studies in
which short-term (1–12h) expression is sufficient,
as the increase in expression in the early stages
post transduction may not be sustained. The suc-
cess in improving expression through increasing
viral number per cell is likely to precede silencing
of the episome.11 For studies in which longer-term
expression of the transgene is required, vector
modifications such as U3 deletions may be neces-
sary to maintain transgene expression after in-
creasing the transduction efficiency.11 Long-term
expression from IDLVs has, however, been dem-
onstrated in several studies, primarily in the liver,
in which coagulation Factor IX has been shown to
be stably expressed from IDLVs in levels compa-
rable to those observed with ILVs.46,47 Yanez-
Munoz et al. have also shown robust long-term
expression of an IDLV-derived transgene following
in vivo application of a GFP-expressing IDLV in
the brain and retinae of mice.48 In vivo transduc-
tion of RPE cells with the RPE65 vector is not a
feasible treatment for dry AMD, as cell replace-
ment, rather than gene replacement, is required.
To improve IDLV3-RPE65 transduction effi-
ciency, the transduction protocol was systemati-
callymodified. Transduction is dependent on direct
virion–cell interaction. Viral particles have a half-
life of around 4–8h,49,50 during which they are
capable traveling 580–610 microns.51 Since both
the cells and the vectors are negatively charged, it
is necessary to enhance the localization of cells and
virions using reagents that either bind both, or
eliminate the negative charge of both the cells and
the virions. RetroNectin enhances transduction
efficiency via co-localization of virions and cells52,53
through binding by a heparin-binding domain and
VLA5/VLA4 binding domains respectively.12,14
RetroNectin is frequently used to maintain retro-
viral gene transfer in hematopoietic stem cells de-
rived from primates, canines, and humans.23,54,55
It has advantages over the commonly used poly-
cation polybrene, which facilitates gene transfer by
counteracting the negative charge of the cells and
virions, in that it is less toxic to cells yet produces
similarly efficient transductions. Protamine sul-
fate has been shown to be as effective as polybrene
with the mouse SAX retroviral vector.56 However,
it was found to be significantly less effective than
polybrene or RetroNectin in BMDCs. Therefore,
the focus was on using RetroNectin to enhance
transduction with IDLV3-RPE65.
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Efficient transduction of the HEL cell line and
human CD34+ cells with retroviral vectors has
been reported on plates coated with 2 lg/cm2 Ret-
roNectin,12 despite the instruction manual indi-
cating a requirement for 4–20lg/cm2. The findings
support these data, indicating that LVs also
transduce both human and mouse BMDCs on 2 lg/
cm2 RetroNectin. Additionally, the study shows
that a single preparation of 2lg/cm2 RetroNectin
can be removed and used to coat up to three wells
before any reduction in efficiency. Both of these
findings minimize the cost of LV approaches using
RetroNectin. Also consistent with the literature, in
which it has been reported that preloading of ret-
roviral vectors on RetroNectin enhances gene
transfer,12 preloading of IDLV on RetroNectin
prior to transduction of cells resulted in a higher
transduction efficiency,12 indicating that preload-
ing is effective for transduction with lentiviral as
well as retroviral vectors.
Expression of the endogenous Rpe65 and
Cralbp genes in murine BMDCs transduced with
IDLV3-RPE65 confirm that the IDLV is func-
tioning in a similar way to the ILV. To confirm
this, it was demonstrated that systemic adminis-
tration of BMDCs transduced with IDLV3-RPE65
or ILV3-RPE65 both resulted in significantly im-
proved visual function in a mouse model of retinal
degeneration that mimics many of the features
of early AMD.57 Furthermore, in agreement with
previous studies,1,2 the BMDCs were recruited to
the RPE layer and reduced retinal degeneration in
comparison to mice receiving treatment with na-
ı¨ve BMDC. An in-depth phenotypic analysis of
the donor cells was not undertaken in this study,
as the primary endpoint was retention of visual
function. However, it has been previously shown
that these RPE65-programmed BMDCs are re-
cruited to the host RPE monolayer and take on an
RPE-like phenotype, including phagocytosis of
photoreceptor outer segments.1,2 In addition,
these cells may play a neuroprotective role in the
degenerating retina.
Expression of CRALBP in human BMDCs
transduced with ILV3-RPE65 or IDLV3-RPE65
indicates that expression of RPE65 in these cells
is functioning in a similar way as expression in
murine BMDCs, and suggests that expression of
this is likely to result in human BMDC differen-
tiation into RPE-like cells. This is of significant
importance for the therapeutic potential of this
technique in humans, which will be the focus of
future studies.
To summarize, use of IDLV3-RPE65 signifi-
cantly reduces the risk of the LV-based approach,
as the number of viral integrations per cell and the
subsequent risk of insertional mutagenesis is
markedly reduced. IDLV3-RPE65 successfully
initiates the expression of endogenous genes,
which is believed to be responsible for the ability of
RPE65-transduced BMDCs to integrate into and
regenerate damaged RPE in mouse models of RPE
degeneration in both murine and human BMDCs.
Efficacy is significantly enhanced by modifying the
transduction protocol with RetroNectin. This ap-
proach is quick and ideal for applications in which
short-term transient expression may be sufficient,
avoiding time-consuming and costly modifications
of the transducing vector.
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